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Abstract
The brain senses inflammatory signals and drives the release of glucocorticoids (GCs) —
potent immunosuppressants— via the activation of the hypothalamic-pituitary-adrenal (HPA)
axis. This inflammation induced HPA axis activation is largely mediated by prostaglandin E2
(PGE2), acting on two subtypes of the PGE2 receptor, EP1 and EP3. Recently, our group
revealed EP3 signaling mechanisms that excite HPA axis regulatory neurons. This thesis sought
to tease out the remaining EP1 signaling mechanisms. Considering that the excitability of HPA
axis regulatory neurons is constrained by GABA A receptor-mediated synaptic inhibition that
relies on low-level intracellular Cl-. We hypothesized that PGE2-EP1 signaling impairs GABA A
receptor-mediated inhibition by increasing intracellular Cl - levels. We used two
electrophysiological approaches (perforated patch and whole-cell recordings) and showed that
PGE2 depolarizes the reversal potential of GABA A receptor currents (EGABA), an indicator of
intracellular Cl- elevation. The effect of PGE2 was mimicked by EP1 agonist and prevented by
EP1 antagonist. The depolarizing shift was slow to develop but became significant by 20 min
post PGE2. Our results indicate that PGE2-EP1 coupling induces a slow depolarizing shift in
EGABA for the excitation of PVN-CRH neurons during inflammation.
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Lay Summary
When the body encounters an injury or illness, it often goes through an immune process called
inflammation. This involves the recruitment of other immune cells to the site of the illness/injury
to initiate defence, cleanup, and repair. The body can regulate the inflammation process via the
activation of a pathway called the hypothalamic-pituitary-adrenal axis (HPA) axis, which
releases hormones called glucocorticoids (GCs) – which are potent immune regulators. The
immune system activates the HPA axis by activating a subset of neurons (parvocellular
corticotrophin-releasing hormone neurons; PVN-CRH neurons) in a brain region called the
hypothalamus. This is achieved via an immune-signalling molecule called prostaglandin (PG)E2.
PGE2 is known to act through two distinct (receptor-based) signaling pathways; EP1 & EP3.
Previously our group showed how the EP3 pathway disinhibits these neurons, allowing their
activation, and driving the HPA axis. This work aims to understand how the EP1 pathway
modulates these neurons. We hypothesized that the EP1 pathway shifts the magnitude and
direction of inhibition in the PVN-CRH neurons. Using electronic recordings (patch-clamp
electrophysiology) from individual neurons, we looked at changes in induced incoming
inhibitory signals in these neurons. We found that inhibition magnitude is weakened or even
reversed in these neurons in the presence of both PGE2 and iloprost (a chemical mimicking
PGE2 that activates the EP1 pathway). Moreover, blocking the EP1 pathway while applying
PGE2 partially prevented this effect. We theorized that this weakening of inhibition would lead
to disinhibition of the PVN-CRH neurons and activation of the HPA axis. We posited that this
EP1 pathway works in compliment to the EP3 pathway to activate the HPA axis during periods
of inflammation. In summary, we demonstrated the consequences of PGE2-EP1 signaling in
PVN-CRH. In the broader scope, this contributes to our understanding of how inflammation and
the brain interface.
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Chapter 1
Introduction
The stress response
All living organisms experience a stress response [1]. That is, in response to a hazardous
extrinsic or intrinsic challenge, the organism must mount a suitable response to promote its
survival. The mammalian stress response – the focus of this thesis – is characterized by two
functionally distinct phases [1–3]. First, an immediate response prepares the body for a rapid
answer to the stressor – activating in a matter of seconds to minutes [3,4]. This first phase –
termed the flight or fight response – is driven primarily by the autonomic nervous system (ANS)
[2,3]. The ANS drives defensive changes like increased heart rate, slowed digestion, and dilated
pupils [3]. Second, a slower hormonal-based response kicks in after tens of minutes [3]. This
response propels several behavioural and physiological consequences to further prepare the body
for the stressor [3]. This slower response is driven by the hypothalamic-pituitary-adrenal axis
(HPA), a neuroendocrine hormonal cascade culminating in the release of glucocorticoids (GCs)
from the adrenal cortex [3].
It should be noted that the stress response is variable among individuals and not as
uniform as outlined above. The exact timing and nature of the response can depend on many
factors, including stress magnitude, genetic predisposition, and metabolic state [1].

An overview of the HPA axis
The HPA axis, which drives the slower stress response, can be described as follows; This
pathway begins from the hypothalamus, more specifically, a nucleus called the paraventricular
nucleus of the hypothalamus (PVN). The PVN contains various neuron types with distinct
physiological functions [5]. The HPA axis is driven by a specific subpopulation of neurons that
express corticotrophin-releasing hormone (CRH) and send their axons to the median eminence
[6–8]. CRH is released at the external zone of the median eminence, an exchange point of the
hypothalamic releasing factors (including CRH and several others) and the hypophyseal portal
circulation [6–8]. CRH gains access through the fenestrated capillary endothelial to the
hypophyseal portal circulation that connects the median eminence and the anterior pituitary [6–
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8]. In the anterior pituitary, CRH signals to corticotrophs, leading to the release of
adrenocorticotropic hormone (ACTH) into the bloodstream [9,10]. Finally, at the endpoint of the
axis, ACTH in the blood signals to the adrenal cortex to release glucocorticoids (GCs) [9]. In
turn, GCs have several effects on the body [11]. The complete effects of GC on the body are too
numerous to cover in this thesis; a non-exhaustive list includes immunomodulation, glucose
metabolism modulation, reproductive modulation, and cognitive effects [11,12]. Crucially, GCs
also provide negative feedback onto the parvocellular-CRH neurons, the pituitary, and brain
areas upstream of parvocellular-CRH neurons, allowing the HPA axis to self-regulate activation
[13]. In order to better detail the initiation of the stress response, we will explore the PVN and
PVN-CRH neurons in closer detail below.

The anatomy and functions of the PVN
The primary function of the PVN - much like the rest of the hypothalamus - is to provide
homeostatic control for the body's various processes [14]. For example, the PVN is known to
play a role in metabolic, osmotic, and cardiac regulation - as well as its aforementioned role in
the activation of the HPA axis [15]. Reflecting the multiple physiological roles, the PVN
contains various neuron types. Classically, PVN neurons are divided into three major classes,
based on their axonal projection targets; Parvocellular, Magnocellular, and Preautonomic
neurons [13]. These classes are further subdivided into different neuron types based on their
neuropeptide/neurotransmitter expression profiles. We will discuss them briefly here:
Parvocellular: As mentioned above, the HPA axis begins with the parvocellular subclass
of neurons. They can be distinguished from other (magnocellular) neuroendocrine neurons in the
PVN based on their relatively small soma size and projection target [6,16]. These parvocellular
neurons project to the median eminence, where they release their functional peptides [6,9]. A
subset of parvocellular neurons synthesizes and releases CRH into the median eminence [6,9]. A
small subgroup of parvocellular-CRH neurons also co-express vasopressin. However, these
neurons are considered parvocellular neurons based on their axonal projection to the median
eminence and are distinct from vasopressin-expressing magnocellular neurons [17]. In addition
to CRH and vasopressin, parvocellular neurons have also been shown to express other peptides
such as thyrotropin-releasing hormone (TRH), somatostatin (SRIF), and growth hormonereleasing hormone (GRF) [9,18].
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Magnocellular: Magnocellular neurons are hormone-releasing (neuroendocrine) cells
that send projections directly to the posterior pituitary (in contrast to the median eminenceprojecting parvocellular neurons), where they release oxytocin and vasopressin [19]. These
neurons are distinguished by their larger cell body size relative to other PVN cells [6].
Magnocellular neurons are critical for fluid osmolarity regulation and the milk ejection reflex,
the roles being divided up to vasopressin releasing cells and oxytocin releasing cells, respectively
[19–23]. In correspondence with this, the magnocellular neurons possess osmo-sensitive ion
channels [21,24].
Preautonomic: Preautonomic neurons are non-neuroendocrine. In other words, they
project to the brain stem and the spinal cord (instead of blood) and regulate the ANS, hence the
‘preautonomic’ designation [25]. Pre-autonomic neurons release a range of peptides, including
vasopressin, oxytocin, angiotensin II, and CRH [7,15]. Functionally, the preautonomic neurons
have been shown to influence cardiac function, blood pressure, and fluid metabolism [22].

The parvocellular neuroendocrine neurons as the gateway of the stress response
The CRH-releasing parvocellular PVN neurons (PVN-CRH neurons) represent the
primary initiation point of the HPA axis and, thereby, the primary integrative point of stress in
the brain. Historically, PVN-CRH neurons have been well characterized for their role in the
stress response. Initially, it was demonstrated that whole ablation of the paraventricular nucleus
impaired hormonal response to stress in the subject [8]. Later, with the advent of more
specialized techniques, the knockdown of CRH suppressed hormonal response to acute stress
[26]. Moreover, the specific knockdown of CRH in the PVN impaired behavioural response to
social stressors [27]. The most well-studied function of PVN-CRH neurons is activating the HPA
axis via their projection to the median eminence. In addition to this, emerging evidence points
towards the importance of CRH release within the PVN via axonal collaterals or somatodendritic
release [28]. The physiological roles of intra-PVN CRH release remain unknown.
As the integrative center of the HPA axis, among other endocrine systems, the PVN-CRH
neurons receive direct and indirect inputs from across the brain. This includes the cortex,
brainstem, limbic system, and adjacent hypothalamic nuclei [3,9,29]. Direct innervations from
the brainstem onto PVN-CRH neurons signal physiological homeostatic stressors rather than
psychogenic stressors [3]. For example, ascending adrenergic and noradrenergic input from the
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nucleus of the solitary tract encodes for physiological stressors like hypoglycemia [3]. In
experimental studies, lesions of the norepinephrine (NE) and epinephrine (E) hindbrain neurons
that project to the HPA axis resulted in impaired GC response to metabolic but not psychological
stressors [30].
‘Higher order' anatomical projections convey psychogenic stressors linked to their
function. The medial prefrontal cortex (mPFC), hippocampus (HC), and amygdala (AM) are best
studied for their role in the cognitive and emotional control of neuroendocrine stress response
[31]. The complexity of their innervation to the PVN reflects the complexity of psychogenic
stressors. All three regions do not send direct projection to the PVN but send poly-synaptic
signals through lower-order GABAergic relays [31]. In general, the hippocampal and mPFC
connections provide excitatory input onto GABAergic relays, thereby inhibiting the PVN
[31,32]. Experimental lesions of the ventral subiculum of the hippocampus impaired the poststress recovery of HPA axis activation in rats [33]. Interestingly, the effects of the hippocampal
lesions are stressor-specific, with lesions impairing response to psychogenic stressors like
restraint stress [32], or novelty [34], but not to systemic stressors like hypoxia [32]. In other
words, the hippocampus exerts inhibitory control over the HPA axis primarily when it is
activated by psychological stress. The amygdala connections provide inhibitory input onto
GABAergic relays; thereby, amygdala activation inhibits the inhibitory interneurons and
disinhibits the PVN [32]. The amygdala represents the primary fear center of the brain. In line
with this, lesions to the central nucleus of the amygdala impaired HPA axis response to
conditioned and contextual fear stimuli (foot shock) [35]. In total, the "indirect" pathway from
the higher brain areas to the PVN reflects the complexity of signal integration underlying
psychological stressors. Regardless, GABAergic signaling is crucial to PVN function.

GABA is a regulator of the stress response
Anatomically, the majority of inputs to the PVN are GABAergic [16,36]. Upstream brain
regions relay their signals through GABAergic interneurons [31,32]. Furthermore,
immunoelectron microscopy studies of the PVN reported that 46-62% of all synaptic input to
parvocellular neurons were GABAergic [36,37]. Functionally, GABAergic manipulations
directly in the PVN resulted in altered HPA axis activation [38,39]. More specifically, GABA A
receptor agonist application attenuated the HPA axis response to restraint stress [39].
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Conversely, a blockade of GABAergic signaling alone (via GABA antagonist bicuculline),
before stressor application, potentiated HPA axis response to restraint stress [39]. In contrast,
glutamate application alone did not evoke a change in HPA axis activation [38]. Instead,
glutamate activated (measured via cFos) adjacent GABAergic interneurons [38], demonstrating
that GABA acts to constrain glutamate-induced activation of PVN neurons [38]. Noradrenaline
mediates its effects – in part – via the GABAergic interneurons, where it has been demonstrated
to have a bidirectional effect on GABAergic signaling [40]. These results indicate that, under
basal conditions, GABAergic signaling is constraining HPA axis response. In total, both
anatomical and functional evidence points towards GABAergic signaling being a potent,
tonically active controller of the stress response that provides gating inhibition to the incoming
excitatory input [38,39]. Therefore, removal of GABAergic inhibition results in rapid activation
of the HPA axis [41]. In other words, GABAergic signaling allows the PVN-CRH neurons to be
primed to respond to stress at a moment's notice. In addition, GABA signaling provides brakes
onto the HPA axis to resolve activation following acute stress [42]. In part, GC signaling in the
brain activates excitatory neurons upstream of the GABAergic interneurons, triggering
GABAergic signaling [43]. This, coupled with GC actions on glutamate in the PVN, allows rapid
resolution of the stress response [42].
Emerging evidence also points towards local-rapid GABAergic signaling in the PVN that
allows rapid PVN-CRH neuron feedback. Experimental studies have demonstrated a local PVN
circuit between PVN-CRH neurons and CRFR1 expressing GABA interneurons immediate to
the PVN [44]. Knockout of CRFR1 expressing neurons in the PVN attenuated resolution of HPA
axis activation [45].
In addition to increasing or decreasing the firing activities of GABAergic neurons
upstream of PVN-CRH neurons, stress changes the modulation of the efficacy of GABAergic
synaptic transmission (i.e., GABA plasticity) in the PVN. More specifically, stress can increase
or decrease the efficacy of GABAergic synaptic transmission via both pre- and postsynaptic
mechanisms. For example, acute stress exposure facilitated the induction of GABA synapses
potentiation in the PVN via an increase in GABA synapse number, dependent on adrenergic
signaling [46]. In contrast, glucocorticoid signaling following acute stress triggered depression of
GABAergic signaling via presynaptic mechanisms that depress the release of GABA-containing
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synaptic vesicles [42,43]. Following chronic stress, depression of GABAergic signaling is
observed [37,47]. One study utilizing patch-clamp electrophysiology found a decrease in
miniature inhibitory postsynaptic current (mIPSC) frequency and amplitude, attributed to a
reduction in GABA synapses [48]. Another study found an overall increase in GABAergic and
glutamatergic synapses following chronic stress in rats [36]. More specifically, they observed an
overall increase in axodendritic GABAergic synapses but a decrease in axosomatic GABAergic
synapses in PVN-CRH neurons [37]. Thus, allowing more temporal and spatial summation of
incoming input in the dendrites before reaching the soma. Since patch-clamp recordings of
miniature inhibitory postsynaptic currents (mIPSC)'s are taken from the soma, the depression in
mIPSC amplitude can be attributed to the loss of axosomatic GABAergic synapses [37]
One well-characterized mechanism of plasticity in GABAergic transmission involves the
alterations in chloride homeostasis. The GABA A receptor, an abundant signaling target of GABA
in the brain, is an ion channel permeable primarily to chloride (Cl -) and bicarbonate (HCO3-) ions
[49]. In healthy adult brains, as GABA binds to the GABA A receptor, the channel opens, and
chloride ion (Cl-) flows into the neuron. The influx of negatively charged ions (i.e., Cl -) causes
hyperpolarization of the neuronal membrane. However, this flow is dependent on the
electrochemical gradient of Cl- across the cell membrane. More specifically, the electrochemical
gradient is determined by two factors (1) the concentration of Cl - on either side of the membrane,
(2) the membrane potential of the neuron (see methods; Determination of [Cl -]i). The membrane
potential at which there is no net flow through the GABA A receptor is referred to as the
equilibrium potential (EGABA; and represents a correlate of Cl- gradient ( as well as HCO3- see
methods, and [41,50]]). When the GABAA receptor opens, Cl- flows down its electrochemical
gradient, attempting to equalize the electrochemical gradient and driving the membrane potential
towards EGABA. Changes in the Cl- concentration gradient can shift EGABA, thus modulating
GABAA – mediated inhibition [41,50].
Chloride homeostasis refers to the neurons' maintenance of this Cl - concentration
gradient. Under basal conditions, the neuron maintains low intracellular Cl - ([Cl-]i) levels such
that EGABA sits at or below resting membrane potential, driving an influx of Cl - after GABAA
receptor opening [41]. In comparison, the buildup of intracellular Cl - can lead to a depolarizing
shift in EGABA and extrusion of Cl- following GABAA receptor opening and subsequent
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depolarization of the neuronal membrane [41]. Such a phenomenon can be seen in the
developing forebrain: many neurons lack the functional proteins to maintain Cl - homeostasis,
leading to the buildup of Cl- within the neuron [51,52]. This causes a depolarizing shift in the
EGABA. In turn, the opening of the GABAA channel allows efflux of Cl- and causes excitation of
the neuron [51,52].
Homeostasis of the Cl- gradient in the forebrain is driven primarily by two ion
cotransporters, NKCC1 (Na+ K+ 2Cl- transporter) and KCC2 (K+ Cl- transporter) [51]. Each
transporter drives Cl- differently, with NKCC1 importing Cl- into the neuron (alongside sodium
and potassium) and KCC2 exporting Cl- (while also exporting K+)[51]. Alterations in NKCC1
and KCC2 function provide a potent mechanism for GABA signaling regulation [53]. As noted
earlier, experimental studies have shown that a lack of functional KCC2 early in development
prevents the cell from exporting Cl-, leading to a buildup of intracellular Cl - and, subsequently,
excitatory GABAergic signaling [51]. In other cases, impairment of KCC2 function (and
subsequent GABAergic signaling dysfunction) has been linked to disorders such as
schizophrenia and epilepsy [54,55].
Notably, changes in EGABA are not limited to early development or pathological
conditions. NKCC1 and KCC2 regulation may represent a potent mechanism of GABAergic
plasticity. For example, cultured hippocampal neurons demonstrate the ability to depress
GABAergic signaling via downregulation of KCC2 function following normal synaptic
stimulation [56–58]. Similar activity-induced KCC2 plasticity has been shown in other CNS
regions, such as the spinal cord [59] and the ventral tegmental area following stress and immune
signaling [60,61].
Critically, plasticity via Cl- homeostasis has also been demonstrated across the
hypothalamus. For example, preautonomic PVN neurons show activity-induced NKCC1 and
KCC2 regulation [62]. Similarly, magnocellular PVN neurons show regulation of Cl homeostasis before lactation or in response to changes in osmotic homeostasis [63,64].
Importantly, evidence indicates that parvocellular PVN-CRH neurons undergo potent plasticity
of Cl- homeostasis via both NKCC1 and KCC2 modulation [41,47,65–67]. PVN-CRH neurons
experience a depolarizing shift in EGABA following acute stress, likely due to a functional
impairment of KCC2 via a Gq mediated pathway [65–67]. Further experiments demonstrated that
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this change depresses GABA signaling during periods of high synaptic activity due to the
accumulation of Cl- within the neuron [68]. Therefore, GABA signaling is conditionally &
temporarily excitatory, facilitating the excitation of the HPA axis following stress. Moreover,
following chronic unpredictable mild stress, PVN-CRH neurons show a biphasic shift in Cl homeostatic regulation. Initially, the neurons show a temporary decrease in KCC2 protein
expression triggering a depolarizing shift in EGABA [47]. Subsequently, the neurons show a return
of KCC2 protein expression to basal levels and an increase in NKCC1 expression, facilitating a
long-term shift in EGABA [47]. However, it is worth noting that simply quantifying the expression
of KCC2 is not enough to infer its function, as KCC2 function is tightly regulated by
phosphorylation, meaning KCC2 expression at basal levels may still not be extruding Cl - as
expected [66,68,69]. In sum, the evidence indicates that Cl - homeostasis is a potent mechanism
of GABAergic signaling plasticity for PVN-CRH neurons. Specifically, PVN-CRH neurons
appear to use modulation of EGABA in a non-pathogenic way to modulate response to incoming
stimuli [41].

The HPA axis, GCs, and the immune system
Inflammation represents one prototypical physiological stress resulting in potent HPA
axis activation (Fig. 1 A). Inflammation can be generally described as the body's response to
injury or invading pathogens [70]. More specifically, inflammation is the recruitment of immune
cells and signaling molecules to the damaged tissue to resolve the infection or injury, and begin
the cleanup and repair of the tissue [71]. In response to, say – a bacterial infection – certain
immune cells will release cytokines to raise the alarm for the rest of the body [71]. When the
magnitude is sufficiently large, activation of inflammatory response in the peripheral tissues, or
any parts of the CNS, can send signals to the brain and activate the HPA axis (Fig. 1 A). For
example, experimental induction of the inflammation response via lipopolysaccharide (LPS) – a
component of the outer membrane of gram-negative bacteria that stimulates an immune response
[72–74] – induced potent activation of the HPA axis via the upregulation of inflammatory
cytokines (e.g. IL-1β and TNFα) by peripheral immune cells [75]. Direct administration of
cytokines (IL-1 β, TNFα) also triggered activation of the HPA axis [76]. Moreover,
administration of LPS increased activation of PVN neurons (measured via cFos) and increased
circulating levels of corticosterone [77]. Ablation of the PVN impaired ACTH response to LPS
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[78]. Thus, inflammation is a powerful physiological stressor inducing the activation of neurons
in the PVN.
In turn, the HPA axis facilitates the resolution of the inflammatory response (Fig. 1 A). In
other words, the HPA axis provides critical negative feedback onto the immune system during
periods of a potent immune response. Overactivation or extended activation of the immune
system can be maladaptive, and as such, it is key that the body can regulate this response via
negative feedback mechanisms [79]. Consequently, disruption of this ability is thought to be
pathogenic in many disorders [79]. In experimental studies, adrenalectomy or hypophyseal
lesions impaired HPA axis response to inflammation and increased the lethality [80–82]. This
HPA axis regulation is partly mediated by GCs, the hormonal output of the HPA axis, because
supplementation of GCs significantly reversed the lethality caused by the surgical disruption of
the HPA axis [82]. GCs are potent immunomodulators, exerting numerous effects on the immune
system [12,83]. During periods of inflammation, GCs act to repress the synthesis and release of
inflammatory cytokines [83]. This is achieved via GC – glucocorticoid receptor (GR) signaling
leading to several transcriptional changes [12,83]. Pharmacological blockade of the GR receptor
results in adrenalectomized-like lethality due to induced inflammation [84]. However, it should
be noted that the roles of GCs in the immune system are very complex [12,83], and extensive
discussion on this matter is beyond the scope of this thesis.

Immune-to-PVN signaling via Prostaglandin E2
While the importance of the HPA axis activation during inflammation is extensively
documented, exactly how signals from the immune system activate PVN-CRH neurons, and
subsequently the HPA axis, remains incompletely understood. Generally, the molecular
mechanism appears to involve a two-stage process:
First, inflammatory cytokine signals, reaching the brain through the general circulation,
binds to endothelial cells & perivascular macrophages and induce upregulation of the
cyclooxygenases pathways (COX-1 and COX-2) [85–87] (Fig. 1 B). Functionally, this means
that inflammatory cytokines do not cross the blood-brain barrier themselves, but instead,
endothelial cells act as a signal transmission method. Next, activation of COX-1 and COX-2
triggers the synthesis of PGs. More specifically, the COX's are involved with the synthesis of
prostaglandin H2 (PGH), a precursor for various PG subtypes H, I, D, E, F [88–90]. In the HPA
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axis activation case, PGH is synthesized into PGE2 [86] (Fig. 1 B). Experimental evidence
indicates that PGE2 but not other PGs mediate inflammation-induced activation since the
pharmacological blockade or genetic ablation of the PGE2 receptors almost completely prevents
HPA activation in response to LPS [86,91]. In turn, PGE2 is then released into the PVN [86,91]
(Fig. 1 B). Finally, PGE2 signaling in the PVN induces activation of parvocellular PVN-CRH
neurons, and subsequently, the HPA axis [85,86,92] (Fig. 1 B).
PGE2 signals through its four receptor subtypes EP1, EP2, EP3, and EP4 [90]. Across the
brain, these receptors mediate differential effects and consequently have distinct downstream
signaling mechanisms [89,93]. All four receptors a G-protein coupled receptors. EP2 and EP4
signal through Gs, causing upregulation of cyclic adenosine 3’,5’-monophosphate (cAMP)mediated pathway [89,90,94]. In contrast, the EP3 signaling pathway is a G i-mediated cAMP
down regulator [89]. Finally, EP1 triggers a Gq-mediated intracellular calcium increase and
activates the protein kinase C (PKC pathway) [89]. Regarding the activation of the HPA axis,
PGE2 primarily exerts its effects through the EP1 and EP3 signaling pathways [91]. In
experiments completed in knockout mouse lines for each of the four receptor subtypes, only EP1
and EP3 knockouts showed impaired ACTH response to LPS, whereas EP2 and EP4 knockouts
showed responses similar to controls [91] (Fig. 1 B). Further studies revealed that
pharmacological antagonism of EP3 impairs the results of PGE2 based activation of PVN-CRH
neurons [95,96] (Fig. 1 B). Furthermore, immunohistochemistry, RT-PCR, and in situ studies
have confirmed EP1 and EP3 receptor subtypes in the PVN [91,95,97,98]. Crucially, such
studies have differently localized the two receptors. EP3 has been localized presynaptically in the
PVN [91,95,99]. On the other hand, EP1 is localized postsynaptically [91,98]. Some studies also
report EP2 and EP4 mRNA localization in the postsynaptic PVN neurons [98,100].
Importantly, the mechanism by which PGE2 modulates PVN activity seems to be
GABAergic in nature. Recent work from our lab revealed an EP3-mediated activation of PVNCRH neurons via GABAergic modulation [99]. Application of PGE2 to ex vivo slices attenuated
incoming GABAergic signal amplitude [99]. This effect could be diminished via the application
of an EP3 antagonist or mimicked via the application of an EP3 agonist [99]. This is congruent
with previous work that showed a decrease in miniature IPSC amplitude and inhibitory
postsynaptic potential (IPSP) frequency following PGE2 application [86] (Fig. 1 B). Subsequent
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to this, there was a depolarization of the membrane potential of PVN-CRH neurons and an
increase in firing frequency [86]. Such results indicate that PGE2, much like other stressors,
activates the HPA axis by inhibiting incoming GABAergic connections, thereby disinhibiting the
PVN-CRH neurons. Thus, our work and those by others (Ferri and Ferguson, 2005; Zhang et al.,
2011) established that the PGE2-EP3 signaling mechanism involves inhibiting GABA release
from the presynaptic terminals to the postsynaptic PVN-CRH neurons, thereby reducing the
amount of inhibition (i.e., disinhibition) (Fig. 1 B). However, a previous EP receptor subtypespecific KO study also indicated an indispensable role of EP1 [91]. The molecular and cellular
mechanistic role of EP1 in mediating activation of the HPA axis is unclear. To better understand
how the HPA axis and the immune system are coupled, it is critical to understand the role of EP1
signaling in the PVN.
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FIG 1 - Hypothesis: PGE2 changes GABAA receptor reversal potential via EP1 signaling in
PVN-CRH neurons
(A) Schematic representation of the inflammation to hypothalamic-pituitary-adrenal (HPA) axis
communication. In short, inflammation induces the release of corticotrophin-releasing hormone
(CRH) from the paraventricular nucleus (PVN) of the hypothalamus. This triggers the release of
adrenocorticotropic hormone (ACTH) from the pituitary. In turn, ACTH stimulates the release of
glucocorticoids (GCs) from the adrenal cortex. GCs provide regulatory feedback to the
inflammatory response. (B) Schematic representation of the inflammation-mediated activation of
the PVN-CRH neurons. (1) Circulating cytokines trigger the release of prostaglandin E2 (PGE2;
yellow) into the PVN [86]. (2) PGE2 acting via its EP3 receptor (orange) presynaptically inhibits
GABAergic (red) signaling, disinhibiting PVN-CRH neurons (blue) [86,91,99]. (3) Knockout
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studies showed the EP1 (expressed postsynaptically in PVN-CRH neurons; green) is necessary
for mediating the HPA axis response to inflammation [91,98]. (C & D) Schematic representation
of our hypothesis: PGE2 changes GABAA receptor reversal potential via EP1 signaling in PVNCRH neurons. (C) Under basal conditions: The equilibrium potential of GABA (E GABA) is
maintained such that GABAA signaling is inhibitory. GABA binding to the GABAA receptor
(grey) triggers the influx of Cl- (orange) down its electrochemical gradient hyperpolarizing the
membrane potential. Neurons maintain the Cl - gradient and thus EGABA via processes involved in
Cl- homeostasis (purple). (D) In the presence of PGE2: PGE2 binding to the EP1 receptor
(Green) disrupts the neuronal maintenance of intracellular chloride concentration [Cl -]i. This
triggers the buildup of [Cl-]i, a depolarizing shift in EGABA, and Cl- efflux on GABAA opening.
This triggers weakened, or even excitatory, GABA signaling. EP1 is a G q couple receptor. Other
Gq coupled receptors in the PVN-CRH neurons have been linked to altered Cl - homeostasis and
depolarizing shifts in EGABA [65].
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Rationale
There are several lines of evidence pointing to the roles of EP1 in the excitation of PVNCRH neurons via GABA synapse plasticity. First, genetic knockdown of EP1 receptor impaired
HPA axis response to inflammation [91] (FIG 1 B). Second, in situ hybridization and
immunohistochemistry showed the postsynaptic localization of EP1 on PVN-CRH neurons
[91,98] (FIG 1 B). Third, the downstream signaling pathways of EP1 – that is, the G q-Ca2+
pathway [90,93] – have been directly linked to the modulation of E GABA. As discussed in "GABA
as a regulator of the stress response" [65,93,101], Cl - homeostasis is one key mechanism
underlying the plasticity of GABAergic synaptic transmission onto PVN-CRH neurons
[41,47,65,68]. Taken together, the general hypothesis of my thesis is as follows:

Hypothesis
PGE2 changes GABAA receptor reversal potential via EP1 signaling in PVN-CRH
neurons.

Aims
To test the hypothesis, we will address the following aims:
1. Using gramicidin-based perforated patch protocol (see methods), measure E GABA in
PVN-CRH neurons before and after PGE2 application.
2. Using whole-cell patch clamp recordings, measure E GABA in PVN-CRH neurons before
and after PGE2 application.
3. Investigate the contribution of EP1 in mediating PGE2-induced E GABA shift. Using an
EP1 agonist, and an EP1 antagonist paired with PGE2
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Chapter 2
Methods and Materials
Animal Handling
All experiments using animals were approved by the Animal Care Committee at the
University of Western Ontario and in compliance with Ontario Animals for Research Act. All
efforts were made to minimize the number of animals used and their suffering. Experiments were
performed using 60-90 day old male CRH-tdTomato reporter mice. The CRH-tdTomato mice are
obtained from an in-house C57BL/6 background crossbred homozygous CRH-IRES-Cre driver
(Jackson Laboratories, stock #: 012704) and a homozygous Cre-dependent ROSA26-tdTomato
reporter (Jackson Laboratories, stock #: 007914). Animals were housed in cages of 3-4 cohorts.
Cages consisted of bedding and a small, red-tinted shelter for environmental enrichment. Food
and water were available as needed.

Slice preparation
Immediately following sacrifice, the whole brain was extracted and placed in ice-cold
(~3C) slicing solution consisting of (NaCl 87 mM, KCl 2.5 mM, NaHCO 3 25 mM, CaCl2*2H2O
0.5 mM, MgCl2*6H2O 7 mM, NaH2PO4+H2O 1.25 mM; glucose C6H12O6 25 mM, sucrose
C12H22O11 75 mM, Osmolarity 320 mOsm, bubbled for 20 minutes). 250uM coronal slices were
prepared using a vibratome (VT1200s, Leica Biosystems). The paraventricular nucleus was
isolated by landmarking the anterior commissure and taking up to 1250uM slices posterior to
this. For patch slice preparation, the vibratome was set to slice at 10 mm/s with a spread of 20
mm. Following slice production, the slices were cut medially along the longitudinal axis. To
ensure the slices would fit in the perfusion chamber, excess tissue (primarily the cortical regions)
dorsally and laterally to the PVN were cropped. The prepared slices were placed in a warmed
(34°C) ACSF (NaCl 125 mM, KCl 2.5 mM, NaHCO3 26 mM, CaCl2*2H2O 2.5 mM,
MgCl2*6H2O 1.5 mM, NaH2PO4+H2O 1.25 mM; glucose C6H12O6 10 mM, Osmolarity 300
mOsm, bubbled for 30 minutes before use and continuously thereafter) bath (Lauda, E100
Ecoline Staredition) and held for 1 hour. Immediately following this period, the slices were
removed from the warm bath (in the incubator) and allowed to warm up to room temperature
(20-25C) before patch-clamp experiments.
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Electrophysiology
Patch-clamp electrophysiology experiments were performed using the setup described in
TABLE 1. During the experiment, slices were placed into a Warner Instruments RC-22C slice
chamber and constantly perfused with warm ACSF (32C). To isolate GABAergic signaling, the
AMPA and Kainate receptor antagonist 6,7-Dinitroquinoxaline-2,3-dione (DNQX) was added to
the perfused ACSF (DNQX; 10 μM, from 50 mM stock dissolved in DMSO, Tocris Bioscience,
CAT no. 0189, CAS: 2379-57-9). The location of the paraventricular nucleus was determined by
locating the dorsal tip of the third ventricle and verifying the presence of CRH+ neurons under
fluorescence at 10x magnification. Once the location of the PVN was verified, the slice was
anchored in the slice chamber using custom-crafted platinum slice weights.
CRH+ positive neurons were located at 40x magnification using fluorescence. Following
localization, the patch pipette was lowered towards the targeted neuron. Immediately before
entering the slice, a small positive pressure was applied to the pipette, and the pipette offset was
compensated for. Next, a gigaseal was achieved between the patch pipette and the targeted
neuron, and pipette capacitance was compensated for. Cells that did not form a gigaseal (>1
gOhm) were discarded. In puff experiments, during the gigaseal stage, the ‘puff’ pipette would
be placed approx. 20-60um downstream from the targeted cells.
In whole-cell patch-clamp experiments, whole-cell was achieved by applying a briefstrong- inwards suction via the mouth. Immediately following the breakthrough, cell health was
monitored by applying a small voltage pulse (+5 mV) while holding the cell at -70 mV. Cells
which did not achieve an access resistance below 20 mOhm or had a membrane resistance below
500 mOhm were discarded. Cells which failed to meet these criteria at any point during an
experiment were excluded from analysis. All recordings were sampled at 20kHz. For voltageclamp experiments, a Bessel filter of 1.6 kHz was applied in multi-clamp commander. For
current-clamp experiments, a Bessel filter of 10 kHz was applied in multi-clamp commander.
Finally, the electrophysiological identity of the cell was confirmed to be parvocellular using a
brief current clamp protocol. First, a holding current (-30 to 30 pA) was applied to adjust the
resting membrane potential to approximately 70 mV. Next, a small hyperpolarizing current (-20
pA) is applied prior to a ladder of depolarizing current (-20 pA - 120 pA; 20 pA steps). The
voltage response waveform was used to identify the cell type by sight based on the principles
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introduced in [102]. Our whole-cell internal solution consisted of K 2ATP 4 mM, Na3GTP 0.3
mM, K-Gluconate 116 mM, KCl 8 mM, Na-Gluconate 12 mM, K 2-EGTA 1 mM, HEPES 10
mM, MgCl2. Our solutions generated a junction potential of 15 mV (whole-cell) and 3.6 mV
(perforated-patch), which were not compensated for in the reported results.
In gramicidin perforated patch experiments, a similar procedure to above was repeated.
The patch pipette was filled with a high CL- solution in combination with the antibiotic
gramicidin (KCl 150 mM, HEPES 10 mM, osmolarity 310 mOsm, ph 7.2; 40 µg/ml Gramicidin
[Sigma-Aldrich-G5002; CAS: 1405-97-6 ]), as outline previously [65]. This solution allowed
prompt monitoring of perforated patch breakthrough. Due to the high Cl - concentration, a
breakthrough would result in a rapid depolarization of EGABA to values > -15 mV [65]. Therefore,
recordings that showed an of EGABA > -15 mV were assumed to have a compromised perforated
patch and were discarded.
The previously termed ‘puff’ protocol was the primary method used to measure the
GABAA mediated Cl- reversal potential during all experimental methods. In sum, the GABA A
agonist muscimol (10 µM; from 100 µM stock dissolved in H 2O, Tocris Bioscience CAT no.
0289, CAS: 2763-96-4) was applied focally through the ‘puff’ pipette using brief air pressure
(picospirtzer II; 10 ms; 10 psi). To assess the Cl- reversal potential, the cell was held in voltageclamp at varying holding potentials (-90 to -30 mV; 10 mV increments). The resulting membrane
current from each puff was recorded (FIG 2A-B). In order to account for slight variations in
current response, each holding step was repeated 5 times, and the averaged response was used
for analysis (see patch-clamp analysis).
To assess the change in Cl- reversal potential under various conditions, drugs were bath
applied via a gravity-based perfusion system (See TABLE 2 for concentrations). To account for
changes induced in reversal potential by technical limitations (see discussion), two different
primary methodologies were used prior-to- and subsequent-to- drug application in whole-cell
patch-clamp:
Within Cell: In this procedure, the same cell was used for reversal potential analysis
throughout the protocol. Following cell breakthrough (see above), the initial reversal
potential would be measured. Subsequent to bath application of the drug, the reversal
potential of the same cell would be measured periodically (5 min intervals) for up to 60
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min post-drug application. In between each puff protocol, the cell health would be
monitored for changes in membrane or access resistance.
Between Cells: In this procedure, multiple cells were patched prior to and following drug
application. This procedure was introduced in attempt to account for technical error
caused by long-term patch-clamp of cells [103]. Prior to drug application, at least three
cells were patched to assess the basal reversal potential. Following drug application, cells
were patched randomly and periodically to assess changes in reversal potential. Cells
were only held long enough to verify cell identity and measure a single reversal potential.
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Equipment Description

Make/Model (Company)

Microscope

Olympus BX51WI (Olympus)

Microscope Camera

IR-2000 (DAGE-MTI)

LED system

X-Cite Series 120Q (Lumen Dynamics)

Amplifier

Multiclamp Commander 700B
(Molecular Devices)

Digitizier

Digidata 1440A (Molecular Devices)

Micromanipulator (patch pipette)

MP-225 (Sutter Instrument Company)

Micromanipulator (puff pipette)

Burleigh PCS-6000 (EXFO Lifesciences)

Bath Temperature Control

TC-324B (Warner Instruments Co.)

Bath Slice Chamber

RC-22C (Warner Instruments Co.)

Air Table

Vibraplane 5702E-3036-31 (Kinetic
Systems)

Pipette Puller

P1000 (Sutter Instrument)

TABLE 1 – Equipment models used in patch-clamp electrophysiology experiments
Drug

Company

Stock

Final Concentration

PGE2

Caymen

in 5 mM stock

1 µM

Chemcial, CAT

dissolved in EtOH

No. 14010, CAS:
363-24-6
EP1 Agonist

Caymen

in 1 mM stock

(iloprost)

Chemical, CAT

dissolved in EtOH

1 µM

No. 18215, CAS:
78919-13-8
EP1 Antagonist

Caymen

in 2.5 mM stock

(GW 848687X)

Chemical, CAT

dissolved in

Item No.

DMSO

10010410, CAS:
612831-24-0

1 µM

20
Vehicle (90%
EtOH)

n/a

n/a

0.01% EtOH dilution
or ~1 µM

TABLE 2 – Drugs bath applied during patch-clamp electrophysiology experiments
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Patch-Clamp Analysis
Determination of [Cl-]i
Currents from the GABAA receptor are mediated primarily by the movement of Cl -, and
HCO3- across the membrane [49]. Including the role of HCO3- we can describe the simplified
relationship between Cl- and the GABAA current as [49,104]:
I

= g

(V

− E

)

Whereas the GABAA induced current 𝐼, is proportional to the conductance of the channel and
driving force of Cl- 𝑔 multiplied by the difference between the membrane potential 𝑉 and the
equilibrium (reversal) potential of GABAA (EGABA). EGABA itself is determined by the Cl-, and
HCO3- . To this end, the equilibrium potential of GABAA across the membrane is determined
partially by two factors (1) the concentration of Cl - and HCO3-, on either side of the membrane,
(2) other anion concentrations. Excluding #2 based on its weak contribution to this drive [105];
we can describe the relationship between (1) and equilibrium potential by the simplified
Goldman-Hodgkin-Katz equation [104]:

𝐸

=

𝑅𝑇
4[𝐶𝐿 −] + [𝐻𝐶𝑂 −]
𝑙𝑜𝑔
𝐹
4[𝐶𝐿 −] + [𝐻𝐶𝑂 −]

Where 𝑅 is the universal gas constant, 𝑇 is the temperature in kelvin, 𝐹 is the faraday constant,
and [𝐶𝐿 −] , [𝐻𝐶𝑂 −] & [𝐶𝐿 −] , [𝐻𝐶𝑂 −] are the ionic concentrations outside and inside
the cell, respectively. Experiments were completed under the assumption that
[𝐶𝐿 −] , [𝐻𝐶𝑂 −] was consistent across spatial and temporal space. With this in mind, we can
compute our theoretical EGABA based on our known ionic composition. Given that E GABA is
proportional to -in part- [Cl-]i, we utilized EGABA as a proxy for measuring changes in internal Cl concentration.
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Patch Method

Cl-

HCO3-

Theoretical EGABA

Concentration

Concentration

(mV)

[Cl-]i

[Cl-]o

[HCO3-]i

[HCO3-]o

Whole Cell

12

136.5

0

26

-64.97

Perforated

150

136.5

0

26

1.44

TABLE 3 – Theoretical EGABA based on known internal and external ionic composition
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Statistical Analysis
EGABA was computed from the recorded ‘puff’ voltage-clamp traces (see methods electrophysiology). To do so, the five sweeps for each holding potential were averaged to
account for noise in the recording. Then, the maximal absolute current amplitude for each
holding potential was calculated. The maximal absolute current amplitude was found with a
search area of up to 1 second following puff (10 ms) application.
Next, the data was organized such that each current (y; dependent variable), was paired
with holding potential (x; independent variable). Then, the data was fit with simple linear
regression in the form of (FIG 2C):
𝑦

= 𝑚𝑥

+𝑏

Where 𝑦 represents the absolute maximal current at holding potential 𝑥. 𝑚 is the slope of the line.
𝑏 represents the y-intercept of the line. The data was fit using the ordinary least squares method.
In this formulation, EGABA is the holding potential at which there is no net current, thus represented
by the x-intercept (FIG 2C). The x-intercept was calculated by setting 𝑦 to 0 and proceeding as
follows:
0 = 𝑚𝑥
𝑥

+𝑏
=

Or alternatively:
𝐸

=

0−𝑏
𝑚

The computed EGABA was used for follow-up analysis. Each recording was independently fit with
linear regression and EGABA. For each recording, the linear fit was confirmed to have a
significantly non-zero slope, otherwise the data was discarded.
In some cases, we desired to pool cell data prior to fitting with linear regression.
However, we observed recording-to-recording differences in current amplitude arising from
intrinsic differences in cell size, receptor expression, and puff pipette localization. Such
differences in current amplitude may skew the resulting averaging and linear fit. To account for
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this, in these analyses, the current was scaled to the range of [-1,1] by the maximum absolute
value. This can be expressed as:
𝐼
Where 𝐼

=

𝐼
𝑚𝑎𝑥 𝑎𝑏𝑠(𝐼)

represents a single current point. 𝐼 represents the full set of current points for that

recording. 𝑚𝑎𝑥( ) and 𝑎𝑏𝑠( ) represent the maximum and absolute functions respectively.
Each recording was scaled independently prior to pooling.
Data was grouped by treatment and time for follow-up analysis. Follow-up statistical
analysis was completed with a two-way ANOVA (treatment x time) wherever possible. Tukey’s
multiple comparisons were utilized as post-hoc analysis. Due to challenges associated with the
long recording time (>30 minutes) destabilizing cell health (in both gramicidin and whole-cell
conditions) [103,106,107], some cells failed to reach the full recording length. Therefore, we
were unable to use a repeated measures two-way ANOVA due to constraints with missing
values. For time-course analysis, data was baselined on a per cohort basis to account for intrinsic
differences between subjects and cells. Otherwise, a student’s unpaired t-test or one-way
ANOVA was used. For reporting, a p-value <0.05 was considered significant.

Software Used
MultiClamp Commander software (Molecular devices) was used for amplifier control
and filtering. Protocol design and recordings were completed using the Clampex software
Clampex 10.7, pClamp, Molecular devices). Averaging and calculation of maximal current
amplitude was completed using the Clampfit software (Clampfit 10.7, pClamp, Molecular
devices).
Linear regression, computation of EGABA, data scaling, and other statistical analyses were
completed using GraphPad Prism 8 (GraphPad Prism 8.3.1 (549), Graphpad Software, LLC).
Figures were generated using GraphPad Prism 8, and Adobe Illustrator CC 2020 (Adobe
Illustrator CC 2020 24.3, Adobe Software). Writing was completed using Microsoft Word
(Microsoft Word 18.2106.12410.0, Microsoft Corporation). References were managed and inset
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using Mendeley, and the Mendeley Microsoft Word Software plugin (Mendeley Desktop 1.19.3,
Mendeley LTD, Elsevier).
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FIG 2 – The assessment of EGABA using patch-clamp electrophysiology and focal application of a
GABAA receptor agonist Muscimol
(A) Schematic representation of patch-clamp recording configuration. The whole-cell or
perforated patch clamp is achieved in a CRH neuron. To activate the postsynaptic GABA A
receptors, muscimol (10 µM) is focally applied using air pressure (10 ms) from a glass pipette
placed approximately 30-60 µm from the soma of the recording neuron. (B). A representative
voltage-clamp trace. The cell is held at different membrane potentials to assess the peak
amplitude and direction of the muscimol-induced current. Each line represents a different
holding potential ranging from -90 mV (bottom) to -40 mV (top). The black bar indicates the
application of a 10 ms muscimol puff. Each red X represents the points at which the maximum
absolute current was observed. (C) The extrapolated I-V relationship was generated from the
patch-clamp recordings. Each red X indicates the absolute maximum current found after the puff.
The black line shows the least-squares linear regression fit to the data (R 2: 0.9925; p < 0.0001).
The x-intercept (-66.40 mV) represents the reversal potential for GABA A receptor-mediated
current in this neuron (black arrow).
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Chapters 3
Results
PGE2 induces a depolarizing shift in EGABA
We hypothesize that PGE2 causes a depolarizing shift in E GABA, which results in a loss of
GABAergic inhibition. To test this, we measured the E GABA before and after PGE2 (1 µM)
application using the perforated patch-clamp technique (see methods). Briefly, we held the postsynaptic membrane potentials at various levels and recorded GABA A receptor-mediated currents
by focally applying muscimol (10 µM), a specific agonist for GABA A receptors (Fig. 2A). We
then plotted the maximal (peak) current response (I) as a function of the holding-membrane
potential (V); the resulting function was fit with linear regression to extrapolate the E GABA. We
found that EGABA was -78.86 ± 7.50 mV (n=14) under the basal conditions with the perforated
patch approach. This is consistent with previous findings in rats and mice [65,66].
In a subset of neurons, EGABA was repeatedly measured at 10-minute intervals during the
baseline (-10 and 0 min) and after drug (PGE2 or drug) applications (10-60 min). Fig. 3B shows
that PGE2 caused a depolarizing shift in EGABA, which was time-dependent and reversible after
the washout of PGE2. On the other hand, vehicle (0.01% EtOH) caused no change. The baseline
EGABA was not significantly different between PGE2 and vehicle groups (PGE2 baseline n=7,
VEH baseline n=7, Tukeys’s; DF=50; PGE2 baseline vs VEH baseline q=0.9791, p=0.8896; see
below). A two-way ANOVA revealed a significant interaction between treatment x time and the
main effects of treatment but not time (n=65; Treatment X Time: F (6, 51) = 5.949, p<0.0001,
Treatment: F (1, 51) = 52.22, p<0.0001; Time: F (6, 51) = 1.130, p=0.3582). Post-hoc analysis
showed a significant difference between baseline (T=-10) and the 10–30-minute time points in
the PGE2 condition (n=7 for all; Tukey’s; DF=51; -10 vs 10: q=5.032, p=0.0135; -10 vs 20:
q=6.921, p=0.0002; -10 vs 30: q=5.339, p=0.0072). In contrast, the vehicle control condition
showed no significant difference between any time points (n=5 for all; Tukey’s; DF=51; q<2.5
for all; p>0.5 for all). We also found that EGABA was significantly higher in PGE2 than vehicle at
time points between 10 and 30 min (n=7 for PGE2, n=5 for VEH; Tukeys’s; DF=51; -10 PGE2
vs -10 VEH: q=0.0899, p>0.9999; 10 PGE2 vs 10 VEH: q=5.410, p=0.0218; 20 PGE2 vs 20
VEH: q=8.992, p<0.0001; 30 PGE2 vs 30 VEH: q=6.194, p=0.0042).
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The time-course measurement of EGABA indicated that the PGE2-induced EGABA shift
becomes evident anytime between 10 and 30 min after the drug application. Thus, we pooled
additional cells whose EGABA was measured at a single time point between 10-30 minutes after
the drug application to compare pre- and post-drug E GABA changes. Fig. 3C shows the pre- and
post-drug I-V curves for PGE2 and vehicle treatments. The I-V curves were normalized per-cell
to a range of [-1,1] to account for the cell-to-cell variability in the absolute current amplitude
(this is primarily due to technical variability arising from the relationship between GABA
applying pipette and the recorded neurons; see methods). The normalization allows averaging
across cells without disrupting slope or x-intercept (see methods). We then compared the
resulting linear regressions for the three conditions (the baseline, post-PGE2, post-vehicle). The
linear regression for each condition was significantly non-zero (simple linear regression;
Baseline: F(1,64)=56.62, p<0.0001; PGE2: F(1,28)=39.73, p<0.0001; VEH: F(1, 10)=18.65,
p=0.0015). The slope between each condition was not significantly different between groups,
indicating that PGE2 does not change the whole-cell GABA A receptor conductance. On the other
hand, the intercepts were significantly different from each other (ANCOVA; slope:
F(2,102)=0.6306, p=0.5343; intercept: F(2, 104)=20.68, p<0.0001), indicating PGE2-induced an
EGABA shift.
In the pooled data, a two-way ANOVA revealed a significant interaction between
treatment and time (two-way ANOVA; n=54; Time x Treatment: F (1, 50) = 18.90, p<0.0001;
Time: F (1,50)=4.646, p=0.0360; Treatment: F (1,50)=9.980, p=0.0027) (Fig. 3 D compares
EGABA for pre- and post-drug application for PGE2 and vehicle). The baselines and VEH
conditions were not significantly different from each other, but both significantly different from
the PGE2 condition (PGE2 baseline n=7, VEH baseline n=7, PGE2 n=23, EtOH n=17; Tukeys’s;
DF=50; PGE2 baseline vs VEH baseline q=0.9791, p=0.8896; PGE2 10-30 minute vs VEH 1030 minute, q=10.34, p<0.0001; PGE2 baseline vs PGE2 10-30 minute, q=6.635, p=0.0001; VEH
baseline vs VEH 10-30 minute, q=2.150, p=0.4334). The mean shift between the PGE2 baseline
and pooled 10–20-minute data was -24.92 ± 5.31 mV (-78.86 ± 7.50 mV, n=7; -56.22 ± 13.49
mV, n=23; respectively).
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FIG 3 – PGE2 induces a time-dependent shift in E GABA.
(A) Representative voltage-clamp trace showing a single unit response to muscimol puffs (black
bar; 10ms) pre- (top, grey) and post- (bottom, orange) PGE2 application. Each trace represents a
different holding potential ranging from -70 mV (bottom) to -30 mV (top). (B) A plot of the
measured reversal potential in respect to time and condition. Application of drug (PGE2
[Orange], VEH [Blue]) occurs at time point 0 (dotted line) and lasts five minutes (grey overlay),
subsequently the drug is washed out. Baseline data recorded at -10min. A two-way ANOVA
revealed a significant interaction between treatment x time (n=65; Treatment X Time: F (6, 51)
= 5.949, p<0.0001, Treatment: F (1, 51) = 52.22, p<0.0001; Time: F (6, 51) = 1.130, p=0.3582).
In the PGE2 condition, post-hoc analysis showed a significant difference between the -10
minute, and 10–30-minute time points (n=7 for all; Tukey’s; DF=51; -10 vs 10: q=5.032,
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p=0.0135; -10 vs 20: q=6.921, p=0.0002; -10 vs 30: q=5.339, p=0.0072) (C) I-V relationship for
each condition. Current amplitude is normalized to [-1,1] for each neuron, and then the average
is computed for each condition. The intercept represents E GABA of each condition and are higher
in PGE2 than the baseline or VEH (ANCOVA; intercept: F(2, 104)=20.68, p<0.0001). On the
other hand, the slopes, which reflect the postsynaptic total GABA A receptor conductance, were
similar between the baseline, VEH and PGE2 (ANCOVA; slope: F(2,102)=0.6306, p=0.5343).
(D) Plot of the recorded reversal potential for each condition. Each point represents a single
measure. The VEH and PGE2 conditions represent data pooled from points recorded in the 10–
30-minute conditions (see results). A two-way ANOVA revealed a significant interaction
between treatments and time (two-way ANOVA; n=54; Time x Treatment: F (1, 50) = 18.90,
p<0.0001; Time: F (1,50)=4.646, p=0.0360; Treatment: F (1,50)=9.980, p=0.0027). The
baselines and VEH conditions were not significantly different from each other, but both
significantly different from the PGE2 condition (PGE2 baseline n=7, VEH baseline n=7, PGE2
n=23, VEH n=17; Tukeys’s; DF=50; PGE2 baseline vs VEH baseline q=0.9791, p=0.8896;
PGE2 10-30 minute vs VEH 10-30 minute, q=10.34, p<0.0001; PGE2 baseline vs PGE2 10-30
minute, q=6.635, p=0.0001; VEH baseline vs VEH 10-30 minute, q=2.150, p=0.4334). ***,
p<0.015. ns (not significant), p>0.05
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Whole-Cell Patch-Clamp effectively detects PGE2-induced E GABA shift
Gramicidin perforated patch-clamp is a commonly used approach to measure E GABA
because it forms pores impermeant to Cl- and thus does not disrupt the cell-intrinsic intracellular
Cl- composition [108]. On the other hand, whole-cell patch-clamp techniques allow the
intracellular cytosol to become continuous with the artificial intracellular solutions in the patch
pipette, which alters the cell-intrinsic intracellular Cl - composition [108]. However, whole-cell
patch-clamp is an important alternative because whole-cell configuration allows us to apply
various drugs through the recording pipette to dissect intracellular signaling mechanisms that
lead to altered post-synaptic Cl- homeostasis. In addition, whole-cell is superior to perforated
patch-clamp for the control of the postsynaptic membrane potential, and as a consequence, the
measurement of EGABA. Importantly, a number of previous studies have effectively used wholecell configuration to measure EGABA changes induced by pharmacological manipulations as well
as behavioural manipulations [65,68,109,110]. This was possible because E GABA reflects a
dynamic balance between the activities of Cl- pumps (KCC2 and NKCC1) and Cl- channels
(GABAA receptors and other Cl- channels) that constantly exchange Cl - across the membrane.
Thus, any changes in the dynamic Cl- balance (e.g. Cl- pump activities) will shift the EGABA even
under the whole-cell configuration [68].
Using the whole-cell patch-clamp approach, we found, in basal conditions, a mean E GABA
of -57.42 ± 4.59 mV, representing a shift of 21.44 mV compared to the perforated patch baseline.
The depolarized EGABA is in line with the predicted EGABA: -64.97 mV, based on the [Cl-]o,
[HCO3-]o and [Cl-]i, [HCO3-]i we used in the experiment. This is congruent with previously
reported values taken in whole-cell experiments [65,68].
To examine PGE2-induced EGABA shift, EGABA was measured before and at various time
points after PGE2 application up to 60 min (Fig. 4 A). Some neurons were repeatedly measured
before and several time points after PGE2 (1 µM) application, whereas some other cells were
measured only at a single time point (see methods). Similar to the perforated-patch
configuration, we found a time-dependent shift in E GABA following the application of PGE2 (Fig.
4 B). A two-way ANOVA revealed a significant interaction between treatment x time (two-way
ANOVA; n=75; Treatment, F(1, 62)=54.45, p<0.0001; Time, F(6,62)=2.831, p=0.0168; Time x
Treatment, F(6,62)=5.763, p<0.0001). Post-hoc analysis of the PGE2 condition showed a
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significant difference between the -10 minute and 20 & 60 minute time points (Tukey’s; n=5;
DF=62; -10 vs 20: q=5.285, p=0.0071, -10 vs 60: q=8.202, p<0.0001), and a significant
difference between 0 minute and 20 – 60-minute conditions (Tukey’s; n=5; DF=62; 0 vs 20:
q=5.456, p=0.0049, 0 vs 30: q=4.440, p=0.0393; 0 vs 40: q=4.744, p=0.0219; 0 vs 60: q=7.409,
p<0.0001). However, the -10 min condition was not significantly different from the 30–40minute conditions (Tukey’s; n=5, DF=62, -10 vs 30: q=3.672, p=0.1449; -10 vs 40: q=4.048,
p=0.0792). In contrast, post-hoc analysis of the VEH condition showed no significant difference
for any time points (Tukey’s; n=5; DF=62; q<2.6, p>0.5 for all). These data indicated that, in the
whole-cell configuration, the PGE2-induced E GABA shift becomes evident between 20-40 min
after drug application.
In order to compare pre- and post-drug conditions, we pooled the data from the 20-40
min bins for further analysis. We assessed the I-V relationship for the baseline and PGE2
conditions (Fig. 4 C). The slope of the line was significantly non-zero for all conditions (simple
linear regression; Baseline: F(1,56)=123.4, p<0.0001; PGE2: F(1,28)=213.6, p<0.0001). Similar
to the perforated patch experiments, the slopes between baseline and PGE2 did not significantly
differ; however, the intercepts did (ANCOVA; slope: F(1,111)=0.2028, p=0.6533; intercept: F(1,
112)=19.08, p<0.0001).
After pooling the data, a two-way ANOVA revealed a significant interaction between
treatment x time (two-way ANOVA; n=91; Treatment: F(1,87)=17.28, p=<0.0001; Time:
F(1,87)=17.46, p<0.0001; Treatment x Time: F(1,87)=15.04, p=0.0105). A post-hoc analysis
showed that the PGE2 and VEH condition baselines did not differ, but the 10-30 min time-points
did (FIG 4 D)(PGE2 baseline n=30, VEH baseline n=13, PGE2 treatment=30, VEH
treatment=18; Tukey’s; DF=87, Baseline PGE2 vs Baseline VEH: q=1.464, p=0.7293; 10–30minute PGE2 vs 10 -30 minute VEH: q=7.169, p<0.0001). The PGE2 condition showed a mean
depolarizing shift of -7.55 ± 1.28 mV compared to its respective baseline (n=30, n=30; Tukey’s;
DF=87; q=8.304, p<0.0001). The VEH control condition did not differ from its respective
baseline (n=13, n=18; Tukey’s; DF=87; q=1.365, p=0.7736). Similar to the baseline, the wholecell PGE2 condition and perforated patch PGE2 conditions showed a significant difference, with
a mean shift of -6.751 ± 2.695 (unpaired t-test; whole cell n=30, perforated patch n=22; t=2,
whole-cell PGE2 mean -49.47 ± 5.71 mV vs perforated-patch PGE2 mean -56.22 ± 13.49 mV).
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In summary, we validated that whole-cell configuration is effective in detecting PGE2induced EGABA shift, as has been shown by other studies [65,68].
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FIG 4 – PGE2-induced EGABA shift measured by whole-cell patch clamp recordings
(A) Representative voltage-clamp trace showing a single unit response to muscimol puffs (black
bar) pre- (top, black) and post- (bottom, red) PGE2 application. Each trace represents a different
holding potential ranging from -70 mV (bottom) to -30 mV (top). (B) Scatter plot of the change
in reversal potentials measured across time for the post-PGE2 (red) and VEH (grey) conditions.
Application of drug occurs at time point 0 (dotted line) and lasts five minutes (grey overlay),
subsequently the drug is washed out. A two-way ANOVA showed a significant interaction
between treatment x time (two-way ANOVA; n=75; Treatment, F(1, 62)=54.45, p<0.0001;
Time, F(6,62)=2.831, p=0.0168; Time x Treatment, F(6,62)=5.763, p<0.0001). Post-Hoc
analysis showed the t=0 time-point and 20–40-minute time points differed for the PGE2
condition (Tukey's; n=5; DF=62; 0 vs 20: q=5.456, p=0.0049, 0 vs 30: q=4.440, p=0.0393; 0 vs
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40: q=4.744, p=0.0219; 0 vs 60: q=7.409, p<0.0001). (C) Mean I-V curves for pre- (black) and
post- PGE2 (red) conditions. Note the 'rightwards' depolarizing shift in the I-V relationship in the
post-PGE2 condition. (D) Extrapolated Cl - reversal potentials for units under basal conditions
(black, n=30, N=8), 20-40-min post PGE2 application (red, n=30, N=7), basal pre-VEH
conditions (dark-grey, n=13, N=4) and 20-40-min post-VEH application (grey, n=18, N=4). A
two-way ANOVA reported a significant difference interaction between treatment x time (twoway ANOVA; n=91; Treatment: F(1,87)=17.28, p=<0.0001; Time: F(1,87)=17.46, p<0.0001;
Treatment x Time: F(1,87)=15.04, p=0.0105). Post-Hoc analysis revealed a significant shift in
the reversal potential of the post-PGE2 condition (compared to pre-PGE2 and post-VEH
conditions [PGE2 baseline n=30, VEH baseline n=13, PGE2 treatment=30, VEH treatment=18;
Tukey’s; DF=87, Baseline PGE2 vs Baseline VEH: q=1.464, p=0.7293; 10-30 minute PGE2 vs
10 -30 minute VEH: q=7.169, p<0.0001][n=30, n=30; Tukey’s; DF=87; q=8.304, p<0.0001].)
***, p<0.0001. **, p<0.05. ns (not significant): p>0.05.
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EP1 mediates the PGE2 induced shift in EGABA in PVN-CRH neurons
Our working hypothesis is that PGE2 depolarizes EGABA via the EP1 receptor. To test
this, we bath applied the EP1 receptor agonist iloprost (1 µM) and examined E GABA changes
using whole-cell patch-clamp recordings. In a separate experiment, we also antagonized the EP1
receptor during the application of PGE2: specifically, we first applied the EP1 competitive
antagonist (GW-848687x, 1 µM), then bath applied PGE2 (1 µM). E GABA was measured before
and at a single time point after the drug application. First, we examined the I-V curves for both
the EP1 agonist and EP1 antagonist conditions. The slope of the baseline, EP1 conditions, and
EP1 antagonist conditions were all significantly non-zero (simple linear regression; Baseline:
F(1, 56)=123.4, p<0.0001; EP1: F(1,33)=107.3, p<0.0001; EP1 antagonist + PGE2:
F(1,22)=96.09, p<0.0001) (Fig 5 B). The EP1 condition showed a significant difference in
intercept but not slope compared to the baseline conditions (ANCOVA; slope: F(1,89)<0.0001,
p=0.9932; intercept: F(1, 90)=14.31, p=0.0003). The EP1 antagonist + PGE2 condition did not
show a significantly different slope or intercept when compared to controls (ANCOVA; slope:
F(1,78)=0.0003, p=0.9855; intercept: F(1, 90)=1.967, p=0.1647) (Fig 5 D).
A one-way ANOVA revealed a significant effect of treatment (one-way ANOVA, n=94;
Treatment: F(3, 90)=19.55, p<0.0001). Following EP1 agonist application, we observed a
significant depolarizing shift in reversal potential comparable to that observed in the PGE2
condition; PGE2 mean -49.47 ± 5.76 mV vs EP1 mean -49.41 ± 3.40 mV (Tukey's; baseline
n=48, PGE2 n = 31, EP1 n=8; DF=90; Baseline vs EP1: q=6.134, p=0.0002; Baseline vs PGE2,
q=10.09, p<0.0001; PGE2 vs EP1: q=0.04518, p>0.9999), indicating that EP1 activation is
sufficient to cause a depolarizing shift in EGABA (Fig 5 A & E). PGE2 application in the presence
of an EP1 antagonist did not induce a significant shift from baseline control but was different
from the post PGE2 condition (Tukey's; baseline n=48, PGE2 n = 31, EP1 n=8; EP1 antagonist +
PGE2 n=7; DF=90; Baseline vs EP1 antagonist + PGE2: q=1.801, p=0.5819; PGE2 vs EP1
antagonist + PGE2: q=3.813, p=0.0410; EP1 vs EP1 antagonist + PGE2: q=3.118, p=0.1298)
(Fig 5 B & E). These results indicate that EP1 is necessary for the PGE2-mediated depolarizing
shift in EGABA.
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FIG 5 - EP1 mediates the PGE2-induced depolarizing shift in E GABA
(A) Representative voltage-clamp trace showing a single unit response to muscimol puffs
(black bar) pre- (top, black) and post- (bottom, green) EP1 (iloprost 1 µM) application. Each
trace represents a different holding potential ranging from -70 mV (bottom) to -30 mV (top).
Note the shift in reversal potential following EP1 wash on. (B) Mean I-V trace for pre- (black)
and post- (green) EP1 conditions. Note the depolarizing shift in the curve. Slopes between the
two lines did not differ significantly but intercept did (ANCOVA; slope: F(1,89)<0.0001,
p=0.9932; intercept: F(1, 90)=14.31, p=0.0003). (C) Representative voltage-clamp trace showing
a single unit response to muscimol puffs (black bar) pre- (top, black) and post- (bottom, blue)
PGE2 + EP1 antagonist (blue, GW-848687x 1 µM). Each trace represents a different holding
potential ranging from -70 mV (bottom) to -30 mV (top). (D) Mean I-V trace for pre- (black) and
post- (blue) PGE2-EP1 conditions. Note that the basal I-V trace occludes the post-PGE2-EP1
trace. Neither slope nor intercept differed between the two lines (ANCOVA; slope:
F(1,78)=0.0003, p=0.9855; intercept: F(1, 90)=1.967, p=0.1647). (E) Extrapolated reversal
potentials for basal conditions (black, n=48, N=8), 20-min post PGE2 application (red, n=31,
N=7), 20-min post EP1 agonist (green, iloprost 1 µM, n=8, N=3), and 20-min post PGE2 in the
presence of EP1 antagonist (blue, GW-848687x 1 µM, n=7, N=3). One-way ANOVA shows a
significant difference between means (one-way ANOVA, n=94; Treatment: F(3, 90)=19.55,
p<0.0001). Post-hoc analysis reveals post-PGE2 condition is significantly different from basal
and PGE2+EP1 antagonist conditions, but did not differ from the post-EP1 condition (Tukey’s;
baseline n=48, PGE2 n = 31, EP1 n=8; DF=90; Baseline vs EP1: q=6.134, p=0.0002; Baseline vs
PGE2, q=10.09, p<0.0001; PGE2 vs EP1: q=0.04518, p>0.9999; Baseline vs EP1 antagonist +
PGE2: q=1.801, p=0.5819; PGE2 vs EP1 antagonist + PGE2: q=3.813, p=0.0410; EP1 vs EP1
antagonist + PGE2: q=3.118, p=0.1298). **, p<0.05. ns (not significant), p>0.05.
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Chapter 4
Discussion
In this thesis, we examined the role of PGE2 and its receptor subtype EP1 in modulating
EGABA in PVN-CRH neurons. In aim 1, we implemented the perforated patch technique in
genetically identified CRH neurons in the PVN of a well-established CRH-reporter mouse line
[18]. We then observed the effects of PGE2 application on E GABA in the PVN-CRH neurons.
Using this technique, we found that the baseline (pre-PGE2) E GABA of PVN-CRH neurons are
similar to that of putative CRH neurons recorded in Sprague-Dawley rats and C57BL/6 mice
[47,65,66]. We found that PGE2 caused a depolarizing shift in E GABA. The result was timedependent, becoming significant by 10 minutes after application and lasting up to 30 minutes.
In Aim 2, we sought to replicate the PGE2 experiments in whole-cell patch clamp
recordings. Despite baseline differences (compared to perforated patch), we observed a similar
depolarizing shift in EGABA following PGE2 application. The depolarizing E GABA shift lasted for
more than 20 min after the washout of PGE2. Notably, in both perforated and whole-cell
experiments, PGE2 did not induce a change in the slope of the current-voltage relationship of the
whole-cell GABAA-mediated currents. However, it did shift the intercept (i.e. E GABA), indicating
that PGE2 primarily changes Cl- homeostasis and does not cause detectable changes in GABA A
receptor function in the postsynaptic cells [41].
In Aim 3, we showed that EP1 agonist (iloprost) induced a slow depolarizing shift in
EGABA, similar to that observed in the PGE2 experiments. Congruent with this, PGE2 application
in the presence of an EP1 antagonist (GW-848687x) attenuated the depolarizing shift in E GABA
introduced by PGE2. Collectively, our data supports the hypothesis that PGE2-EP1 signaling
mediates a post-synaptic shift in EGABA in PVN-CRH neurons.

PGE2 triggers a depolarizing shift in EGABA in PVN-CRH neurons in perforated
patch
Previous studies showed plasticity in EGABA in putative PVN-CRH neurons due to various
stressors [41,47,65]. These studies employed a gramicidin perforated patch technique to measure
EGABA in the absence of intracellular cytoplasmic disruption [65,108]. However, the noted
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studies were conducted in Sprague-Dawley rats or C57BL/6 mice where definitive identification
of CRHergic cell-type were not conducted [65,66]. We first sought to implement the same
technique in the transgenic CRH-IRES-Cre; Ai14 mouse line. This mouse line (with a C57BL/6
background) expresses the fluorescent reporter tdTomato driven by the CRH promotor gene, thus
allowing rapid, visual identification of CRH neurons in acute PVN slices. In this mouse line,
applying the perforated patch technique required slight adjustment compared to the previously
reported methodology. More specifically, we utilized a slightly lower concentration of
gramicidin (40ug/ml) compared to the 60-50ug/ml reported in the literature [65,66]. Higher
concentrations facilitated rapid break down of the cell membrane, and lower concentrations
resulted in too high of an access resistance. The reasons for this modest discrepancy remain
unknown. Regardless, we measured an E GABA of -78.86 ± 7.50 mV in the basal condition,
congruent with the previously reported values [47,65,111].
Next, we examined the time course of the effects of PGE2 on E GABA in these PVN
neurons. To do so, we repeatedly measured E GABA in 10-minute intervals following a 5-minute
wash-on of PGE2. PGE2 induced a relatively slow depolarizing shift in E GABA. We observed a
significant shift in EGABA that onset 20 minutes after PGE2 wash on (15 minutes after washout).
This effect lasted up to 40 minutes after wash-on. Grouping together the 20–40-minute
conditions, we noted depolarizing shift of E GABA to -56.22 ± 13.49 mV. We examined the
relationship between the evoked current in response to the held membrane voltage by fitting this
relationship with a simple linear regression (see methods). Importantly, the slopes between the
baseline and + PGE2 conditions did not change, indicating that PGE2 does not change the
whole-cell GABAA receptor conductance (e.g. potentiation of receptors, synaptic formation, etc.)
[41,104,112]. Instead, the change in y-intercept indicates a shift in E GABA. Together the evidence
points towards a mechanism of PGE2 based disinhibition of PVN-CRH neurons. That is, PGE2
induces a shift in EGABA that weakens GABAergic signaling, thereby leading to disinhibition.
Interestingly, this effect mirrors previously reported shifts in E GABA following the application of
KCC2 inhibitor furosemide and acute stress [65], pointing to a possibility that PGE2 impairs
KCC2 function.
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Whole-Cell patch clamp replicates the PGE2 induced depolarizing shift in E GABA
The whole-cell patch clamp configuration disrupts the cell’s intracellular chloride
composition [108,113,114]. This is due to the diffusion of the patch pipette solution in the
cytoplasm [108,113,114]. Thus, depending on the intracellular solution composition and the cell
being patched, the ion concentration inside the neuron may drift to non-physiological levels
[113,114]. Indeed, Hewitt et al. 2009 reported that whole-cell patch-clamp induced a
depolarizing shift in EGABA in PVN-CRH compared to basal perforated patch recordings [65].
However, Hewitt et al. 2009 also noted that whole-cell patch-clamp was still effective in
detecting a depolarizing shift in EGABA induced by a KCC2 inhibitor furosemide. Furthermore,
Wang et al. 2015 noted that shifts in EGABA were comparable between whole-cell and perforated
patch recording (in the hippocampus) [115]. Finally, Lanz et al. 2020, showed that relative
changes in Cl- homeostasis could still be tracked in whole-cell patch-clamp recordings from
PVN-CRH, despite a shift in the absolute EGABA values due to the replacement of intracellular Cl [68].
In line with these previous studies [65,68], we observed an E GABA of -57.42 ± 4.57 mV
under basal conditions. In addition, following PGE2 application, we saw a depolarizing shift of
EGABA to -49.47 ± 5.71 mV. This shift followed a similar time course to that seen in the
perforated patch conditions, becoming significant by 20 minutes, but did not wash out by 40
minutes. The shift is smaller than that observed in the perforated patch experiments (whole-cell 7.55 ± 1.28 mV vs perforated patch -24.92 ± 5.31 mV). Further analysis of the current-voltage
relationship showed a similar shift in intercept but not in slope.
Interestingly, the shift is similar to that reportedly induced after in vivo stressors [47,65].
In sum, the evidence indicates that in whole-cell patch-clamp, the effect of PGE2 on E GABA could
be observed.
The reasons for the smaller long-lasting shift in EGABA in the whole-cell configurations
compared to the perforated patch configurations are unclear. It could be that the diffusion of
patch solution into the cell ‘clamps’ the intracellular Cl - level to that of the patch pipette. Thus,
we are unable to see rapid, strong shifts in EGABA as the somatic level of [Cl-]i will rapidly return
to that of the pipette [68]. Alternatively, since the E GABA’s in both conditions seem to max out
around the same membrane potential, we are viewing a ‘ceiling’ effect of [Cl -]i buildup [50].
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PGE2-EP1 signaling mediates the depolarizing shift in EGABA
A previous study that used EP1 knock-out mice demonstrated the necessity of EP1 in
mediating the immune-induced activation of the HPA axis [91]. Furthermore, EP1 has been
localized in the soma of PVN neurons [91,98]. Despite this evidence, the mechanism of PGE2EP1 signaling in the PVN neurons remained unknown.
Here, we demonstrated that application of the EP1 agonist iloprost (1 µM) induced a
depolarizing shift in EGABA. In our experiments, the iloprost application mimicked the effects of
PGE2 application – a slow depolarizing shift in E GABA. In addition, similar to PGE2, there was
no significant difference in the slope of the I-V curve but a significant shift in slope. This
indicates EP1 induces non-synaptic changes in GABAergic signaling. Furthermore, the
application of PGE2 in the presence of a competitive EP1 antagonist (GW 848687X; 1 µM)
prevented PGE2-induced EGABA shift. However, this prevention was only partial, as we still
observed a small yet significant shift of EGABA in the PGE2 + EP1 antagonist condition compared
to the no-drug baseline. This is likely due to incomplete antagonism by the antagonist at the
combination of drug concentrations used in the experiments.

Potential Mechanism of EP1 based depolarizing shift in E GABA
Our observation that PGE2-EP1 induces changes in EGABA is in line with previous work.
In the spinal cord, PGE2 has been directly linked to changes in E GABA, with relevance to the
mechanisms underlying inflammatory pain [116]. Furthermore, molecular pathways downstream
of EP1 are linked to modulation in EGABA. Specifically, EP1 is a Gq-linked GPCR [89,90]. Gq
exerts its downstream effects via parallel pathways: (1) release of intracellular calcium stores and
(2) activation of PKC [117,118]. These pathways have distinct bidirectional effects on E GABA
[118]. In the hippocampus, intracellular calcium signaling has been linked to dephosphorylation
of KCC2, and subsequently, a depolarizing shift in E GABA [58,119]. Conversely, PKC signaling
in the same neurons leads to phosphorylation and enhancement of KCC2 function, leading to a
hyperpolarizing shift in EGABA [120,121]. Direct experiments demonstrated that PKC and Ca 2+
signaling pathways work concurrently to counteract their respective counterpart's effects [118].
Furthermore, in the PVN, activation of the α1 adrenergic receptor (AR)-induced a depolarizing
shift in EGABA similar to that observed here [65]. α1-AR is, same as EP1, a G q-coupled GPCR
that results in the release of intracellular Ca2+ and concurrent activation of PKC [65,101]. This
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evidence guides the future directions of our study - to tease out specific downstream mechanisms
for the PGE2-EP1-mediated EGABA shift.

Implications in the broader scope of PGE2 signaling in the PVN
As detailed in the introduction, EP3 and EP1 have been implicated in immune-induced
activation of the HPA axis [91]. Earlier studies showed that PGE2 and EP3 agonists in vivo and
in ex vivo brain slices downregulate GABAergic signaling onto PVN-CRH neurons [86,95,96].
Leading to disinhibition of the HPA axis [86]. Recent work from our lab elucidated the exact
synaptic mechanism of EP3 action [99]. We demonstrated that EP3 agonist application (L 798,106) triggers suppression of GABA release onto PVN-CRH neurons from the presynaptic
terminals [99]. Furthermore, this effect onset rapidly and lasted up to 15 minutes [99]. In
comparison, this work demonstrated that EP1’s effects show a relatively slow onset (~15-20
minutes) and can last up to 40 minutes post washout (see results). EP1 thereby may represent a
method for long-term activation of the HPA axis during periods of high inflammation. In this
theoretical model, EP3’s effects set in rapidly following the detection of acute inflammation in
the PVN; over time, the presynaptic effects of EP3 fade. In periods of sustained inflammation,
EP1 signaling kicks in and weakens GABAergic input overall to PVN-CRH neurons on a longer
time scale. Supporting this, EP3’s effects operate on a ‘per-synapse’ basis, meaning some
GABAergic signaling may still be operating at basal levels [104]. In contrast, EP1’s effects are
post-synaptic and cell-wide, meaning regardless of other GABAergic synaptic changes, GABA
integration will be altered neuron-wide [50]. Further supporting this, the binding affinity of
PGE2 for EP1 is much weaker than the binding affinity for EP3 [90,122]. Indicating, that EP3
shows increased sensitivity to weaker inflammation than EP1 [94].

Limitations
As noted previously, whole-cell patch-clamp can introduce errors into the measurements
of ionic equilibrium [68,108,113,114]. This is due to the diffusion of the internal patch-clamp
solution into the cytosol of the cell [108,113,114]. This results in artificial changes in ionic
concentration and subsequently shifts in the equilibrium potential (see methods) [108,114].
Furthermore, long recording times – such as those used in this experiment – may facilitate
complete diffusion between the two compartments [114], and thus skew the measurement of
EGABA. In our experiments, we addressed this potential limitation as follows: First, we validated
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the role of PGE2 signaling using the gramicidin perforated patch technique. Gramicidin creates
small ionophores within the cell membrane that allow ions (namely Na + and K+) to pass thru, but
crucially, not Cl- [108]. This allows the command of the membrane potential without disrupting
intracellular Cl- concentration [108]. Using this, we validated the effects of PGE2 on Cl -. In
addition, for our whole-cell experiments, we performed both within-cell and between-cell
recordings for our drug wash-on (see methods). In ‘within-cell’ experiments, the same cell was
held prior-to and following drug wash-on for up to 60 minutes. To account for the errors
introduced by long recording times, we also introduced ‘between-cell’ experiments. In ‘betweencell’ experiments, cells recordings were initiated (i.e., whole-cell configuration was obtained) in
separate cells before and after drug application. Cells were only held for a short time period to
complete the EGABA measurement (~5 minutes).
In our experiments, we used EtOH (final concentration 0.01%; ~1 µM) as a vehicle to
dissolve PGE2, EP1 agonist, and EP1 antagonist. This has the potential to introduce error
because EtOH is a potent modulator of GABAergic signaling in the CNS [123]. The precise
effects are brain region-dependent [123,124]. For example, in the amygdala, EtOH
administration (44mM) potentiated GABAergic signaling [125]. To control for this, we
introduced a vehicle control (EtOH; 0.01%; ~1 µM) in both perforated- and whole-cell patchclamp experiments. Notably, wash-on of ethanol alone seemed to induce no significant effect on
EGABA when measured via the muscimol puff method (for both perforated and whole-cell
experiments). Indicating that the EtOH vehicle at the concentration used in this experiment did
not cause detectable changes in EGABA.
This experiment specifically measured the effect of PGE2 on changes in somatic [Cl -]i
homeostasis. The theoretical discussions above and below operate under the assumption of an
isopotential neuron, and therefore somatic [Cl -]i homeostasis influences GABA signaling cellwide. In reality, the interaction between dendritic-, somatic-, axonal- compartmentalization, and
localization of [Cl-]i homeostatic mediators (KCC2, NKCC1) creates a complex gradient of Cl across the neuron [104]. In turn, EGABA can be temporally and directionally different depending
on the synapse localization [104]. Recent work by Lanz et al. 2020 suggests a distinct temporal
difference between [Cl-]i extrusion in the dendrites and soma of PVN-CRH neurons [68]. More
specifically, following acute stress, the Cl -gradient collapsed rapidly in synaptic compartments
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during periods of high-frequency synaptic stimulation, leading to excitatory GABAergic
signaling [68]. In comparison, the somatic Cl -gradient was shown to be much more robust to
high-frequency stimulation and did not collapse into excitatory GABAergic signaling following
acute stress [68]. Further experiments will be needed in order to understand how PGE2 – E GABA
relationships are shaped spatially within the cell.

Future Directions
As noted above, one important future study is to tease out the intracellular molecular
pathways which mediate the PGE2-EP1 effect on PGE2. Our prediction is that EP1, through G q,
triggers downregulation of KCC2 function (see Potential Mechanism of EP1 based depolarizing
shift in EGABA). In turn, the cell cannot regulate Cl - homeostasis, and we see a depolarizing shift
in EGABA. Based on this theory, we can generate two potential hypotheses for further testing: (1)
the intracellular application of a calcium chelator (e.g. BAPTA) should block this signaling
pathway and prevent the modulation of EGABA (as demonstrated in [57,58]). (2) Considering that
PKC counteracts the effects of Ca2+ signaling, the intracellular application of a PKC inhibitor
(e.g. calphostin) should enhance the depolarizing shift (as demonstrated in [118]). (3) an
application of KCC2 inhibitor furosemide should mimic and occlude the effect of PGE2
signaling on EGABA (as demonstrated in [47,65])
The stress response shows sexual dimorphism in its magnitude and temporal
characteristics [126–128]. Reflecting this, the PVN-CRH neurons show sexual dimorphism in
their electrophysiological [129] and molecular [126,128,130] characteristics. Similarly, the
immune system functions in a sexually dimorphic manner [126,131]. Moreover, the interaction
between the immune system and the HPA axis shows sex differences [126,128,132].
Endogenous PGE2 release via astrocytes in the hypothalamus triggers activation of
gonadotropin-releasing hormone (GnRH) neurons, a pathway necessary in female maturation
and ovulation [133,134]. Combined, the evidence points towards a potential sexual dimorphism
in the pathways explored here. The present study was completed only on male mice. Future
experiments should include a female cohort. Given the above evidence, we anticipate a potential
sexually dimorphic response to the application of PGE2 on PVN-CRH neurons.
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Significance & Conclusion
The interaction between the HPA axis and the immune system is critical in the regulation
of immune and stress responses in the body [117,135]. GCs functions as a critical negative
feedback signal onto the immune system [12]. Previously studies showed that PGE2 via EP1 and
EP3 mediates the immune-induced activation of the HPA axis [86] [91].
Our project revealed the ability of PGE2-EP1 signaling to cause a depolarizing shift in
EGABA, which will result in disinhibition (excitation) of PVN-CRH neurons. These results are
congruent with other results showing shifts in E GABA as a form of metaplasticity in the PVN [14].
In addition, we theorized the potential implications of these results in conjunction with other
PGE2 signaling pathways in the PVN. We theorized that the longer time scale of PGE2-EP1
signaling observed here complements the shorter time scale of PGE2-EP3 signaling we
previously reported [136]. This may represent the ability of the PVN to respond biphasically to
inflammation.
In the broader scope, the results here could have potential clinical implications. Dysregulated
immune to HPA communication has been implicated in many conditions [137], including sepsis
[138], HIV [139], and depression [132]. PGE2 synthesis inhibitors (such as COX inhibitors)
have been investigated as a therapeutic for psychiatric disorders [140]. A better understanding of
the mechanistic pathways by which inflammation activates the HPA axis – such as the result
achieved here – creates the potential for more specific therapeutic interventions down the line.
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